Literature DB >> 16273027

Behavioral and neuropsychiatric outcomes in Alzheimer's disease.

Jeffrey L Cummings1.   

Abstract

Behavioral and psychological symptoms of dementia pose significant challenges in the management of patients with Alzheimer's disease. Neuropsychiatric symptoms are associated with cognitive decline, highly impaired activities of daily living, and frontal lobe pathology. Moreover, behavioral and psychological symptoms can diminish patient quality of life, increase caregiver distress, and accelerate nursing home placement. Although these symptoms are often associated with the later stages of Alzheimer's disease, a high percentage of individuals with mild cognitive impairment or mild Alzheimer's report symptoms as well. This article provides an overview of behavioral and neuropsychiatric symptoms associated with Alzheimer's disease and discusses nonpharmacologic and pharmacologic approaches to the management of such symptoms. For patients with severe behavioral and psychological symptoms of dementia, psychotropic agents may be warranted, whereas approved therapies for Alzheimer's, including cholinesterase inhibitors and the N-methyl-d-aspartate receptor antagonist memantine, may be appropriate in less severe cases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16273027     DOI: 10.1017/s1092852900014206

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  11 in total

1.  Behavioral disturbance in dementia.

Authors:  Abhilash K Desai; Lori Schwartz; George T Grossberg
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

Review 2.  Psychotropic medication use for behavioral symptoms of dementia.

Authors:  Philip S Wang; M Alan Brookhart; Soko Setoguchi; Amanda R Patrick; Sebastian Schneeweiss
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

3.  OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE.

Authors:  James E Galvin
Journal:  Neurodegener Dis Manag       Date:  2012-06

4.  Key neuropsychiatric symptoms in common dementias: prevalence and implications for caregivers, clinicians, and health systems.

Authors:  Tatiana I Sadak; Jodie Katon; Cornelia Beck; Barbara B Cochrane; Soo Borson
Journal:  Res Gerontol Nurs       Date:  2013-09-25       Impact factor: 1.571

5.  Course of neuropsychiatric symptoms during a 4-year follow up in the REAL-FR cohort.

Authors:  S Gonfrier; S Andrieu; D Renaud; B Vellas; P H Robert
Journal:  J Nutr Health Aging       Date:  2012-02       Impact factor: 4.075

Review 6.  Pharmacological treatment of the psychosis of Alzheimer's disease: what is the best approach?

Authors:  Subramoniam Madhusoodanan; Payal Shah; Ronald Brenner; Sanjay Gupta
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Spatial navigation deficit in amnestic mild cognitive impairment.

Authors:  Jakub Hort; Jan Laczó; Martin Vyhnálek; Martin Bojar; Jan Bures; Kamil Vlcek
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-28       Impact factor: 11.205

8.  Depression, cognitive impairment and dementia: Why should clinicians care about the web of causation?

Authors:  Mary Ganguli
Journal:  Indian J Psychiatry       Date:  2009-01       Impact factor: 1.759

9.  Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study.

Authors:  K F Huybrechts; T Gerhard; S Crystal; M Olfson; J Avorn; R Levin; J A Lucas; S Schneeweiss
Journal:  BMJ       Date:  2012-02-23

10.  Rivastigmine in the treatment of patients with Alzheimer's disease.

Authors:  Thomas Müller
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.